title: Clinical study of Lipo PGE1-inhibiting platelet activation in acute rejection after kidney transplantation.
abstract: To observe the efficacy of the platelet activation inhibitor Lipo PGE1 therapy in the recovery of graft function after an acute rejection episode after kidney transplantation. Forty patients with acute rejection after kidney transplantation were randomly assigned into groups treated with or without Lipo PGE1. The expression levels of CD61, CD63, and PAC-1 on platelet surfaces were assayed by flow cytometry. The recovery time for graft function and 1-year patient and graft survival rates were recorded. Compared with controls, the expression levels of CD61, CD63, and PAC-1 were lower among acute rejection patients who received Lipo PGE1 therapy. The recovery time for graft function was shorter and the 1-year patient and graft survival rates higher. Lipo PGE1 therapy in patients with acute rejection episodes may inhibit platelet activation thereby benefiting graft functional recovery. The 1-year survival rates of patients and grafts might be increased if the expression levels of CD61, CD63, and PAC-1 on the platelet surfaces was decreased by Lipo PGE1 therapy.
authors.affiliation: Department of Urology, Beijing Chaoyang Hospital, Affiliate of Capital University of Medical Sciences, Beijing, China. liangxlu@163bj.com
authors.forename: Y
authors.initials: Y
authors.lastname: Zhang
authors.forename: D L
authors.initials: DL
authors.lastname: Guan
authors.forename: C Q
authors.initials: CQ
authors.lastname: Xia
authors.forename: Z Y
authors.initials: ZY
authors.lastname: Han
authors.forename: J J
authors.initials: JJ
authors.lastname: Xu
authors.forename: J Z
authors.initials: JZ
authors.lastname: Gao
authors.forename: K R
authors.initials: KR
authors.lastname: Wu
mesh_terms: D000328:Adult; D000527:Alprostadil / Q000627:therapeutic use*; D015703:Antigens, CD / Q000097:blood; D001706:Biopsy; D005260:Female; D005434:Flow Cytometry; D006084:Graft Rejection / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D006085:Graft Survival; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D016030:Kidney Transplantation / Q000276:immunology* / Q000401:mortality / Q000473:pathology; D008297:Male; D008875:Middle Aged; D015539:Platelet Activation / Q000187:drug effects; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D011379:Prognosis; D016019:Survival Analysis; D014184:Transplantation, Homologous / Q000473:pathology
chemical_list: D015703:Antigens, CD; D007166:Immunosuppressive Agents; D010975:Platelet Aggregation Inhibitors; D000527:Alprostadil